Clinical Trials

Clinical Trial Detail

Return to search results.

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Research Study Number       2368.00
    
Principal Investigator       Mohamed Sorror, MD, MSc
    
Phase       NA

Look up trial at NIH

Research Study Description

The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years to 80 Years

Genders Eligible for Study: Both

Sampling Method: Non-Probability Sample

Study Population:

The study population will include non-M3 AML and high-risk MDS patients considered for induction chemotherapy at FHCRC and the Seattle Cancer Care Alliance Network and five other Core institutions (Stanford School of Medicine, Cleveland Clinic, Northwestern University, Massachusetts General Hospital, and University of Utah) in addition to an unidentified number of affiliate sites. We anticipate enrollment of a total sample of 1000 patients.

- Patients with new diagnoses of non-M3 AML or high-risk MDS who present for AML-like treatment that could plausibly produce a complete remission (CR); for example intensive induction chemotherapy, low dose single agent chemotherapy, hypo-methylation agent, or a similar therapy

- Explicitly intend to establish follow-up care at one of the collaborating institutions.

- Patients of =18 years of age and are being treated by the adult AML service.

- Able to read and speak English.

- Willing and able to provide informed consent.

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients of =17 years of age or who are =18 and receive treatment under the pediatric AML service.

- Patients older than 80 years

- Patients with <6 months projected survival due to active second malignancy or other medical problem

Other exclusion criteria may apply.



Research Study Number       2368.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.